Nigel Horscroft D.Phil. is Chief Scientific Officer and Executive Vice President for Preclinical Research at Atriva Therapeutics, a German biopharmaceutical company developing antiviral therapies. Dr. Horscroft holds a D.Phil. in Biochemistry from Oxford University where he studied Bluetongue Virus replication and was a post-doctoral researcher at the University of California-Irvine working on Borna Disease Virus. He worked on Hepatitis C Virus and broad-spectrum antivirals at Valeant Pharmaceuticals in the US and Pfizer in the UK before leading research in the wider drug discovery arena. He has served as Head of Research at PiKe Pharma in Switzerland, Therapeutic Area Head – Molecular Therapy at CureVac in Germany, and CSO at MRM Health in Belgium.